Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Supernus Pharmaceuticals is reaping the benefits of its ADHD drug Qelbree, with strong Q3 results and upwardly revised ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Clinical trials suggest that the drugs seem to treat a host of other conditions, too, including addiction, Parkinson’s ...

What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An ...

Data of Blarcamesine confirm upstream SIGMAR1 activationPresented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease ...

Olfactory dysfunction links to 139 conditions, with inflammation playing a key role in memory decline and cognitive issues.